Gondola Bio shares information about the upcoming PATHWAY clinical trial for PORT-77, a new potential treatment for EPP & XLP.

The webinar explores:

• Current research in EPP and XLP

• The science behind PORT-77

• What GondolaBio has learned from earlier clinical research

• An overview of the upcoming PATHWAY clinical trial

PORT-77 is an investigational medicine and has not been approved by any regulatory authority.

Want to learn more about participating in the PATHWAY clinical trial? Complete this interest form to learn more.